Edwards Lifesciences (EW) Restructuring Costs (2010 - 2025)

Edwards Lifesciences' Restructuring Costs history runs 14 years deep, the most recent figure standing at $208.6 million for Q4 2025.

• On a quarterly basis, Restructuring Costs rose 2681.33% year-over-year to $208.6 million in Q4 2025; TTM through Mar 2026 was $303.2 million, a 579.82% increase from a year earlier, with the FY2025 full-year figure at $325.4 million, up 705.45% from the prior year.
• Restructuring Costs climbed to $208.6 million in Q4 2025 per EW's latest filing, from $90.4 million in the prior quarter.
• Across five years, Restructuring Costs topped out at $208.6 million in Q4 2025 and bottomed at -$2.4 million in Q3 2022.
• The 5-year median for Restructuring Costs is $7.1 million (2021), against an average of $33.8 million.
• Across the five-year window, Restructuring Costs plunged 151.06% in 2022 and soared 2681.33% in 2025, its largest moves.
• Year by year, Restructuring Costs stood at $7.1 million in 2021, then surged by 602.82% to $49.9 million in 2022, then slumped by 80.16% to $9.9 million in 2023, then slipped by 24.24% to $7.5 million in 2024, then surged by 2681.33% to $208.6 million in 2025.
• Per Business Quant, the three latest EW Restructuring Costs figures stand at $208.6 million (Q4 2025), $90.4 million (Q3 2025), and $4.2 million (Q2 2025).